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Introduction {#s1}
============

Cancer stem cells (CSCs) are defined as a unique subpopulation in tumors that possess the ability to initiate tumor growth and sustain self-renewal [@pone.0110736-Clarke1]. It has been proposed that they can cause the heterogeneous lineage of cancer cells that constitute the tumor as well as play an important role in the malignant progression of carcinoma, such as distant metastasis, recurrence, and chemoresistance [@pone.0110736-Yashiro1]--[@pone.0110736-Glinsky1]. CSCs were initially identified in acute myeloid leukemia [@pone.0110736-Bonnet1], but have recently been reported to exist in a wide variety of cancers, including gastric cancer [@pone.0110736-Takaishi1]. The identification of CSC markers may open a new therapeutic perspective on the basis of selectively targeting this small population of cells [@pone.0110736-Stojnev1], [@pone.0110736-Hartgrink1]. Recently, it has been reported that CSCs possibly do express their own unique markers, such as aldehyde dehydrogenase 1 (ALDH1) [@pone.0110736-CharafeJauffret1], CD44 [@pone.0110736-AlHajj1], [@pone.0110736-Li1], and CD133 [@pone.0110736-RicciVitiani1]. However, many of the published markers are not unique to CSCs. Quantitative protein expression profiling allows efficient identification of accurate and reproducible differential expression values for proteins [@pone.0110736-Chen1]. Isobaric tags for relative and absolute quantitation (iTRAQ) combined with multidimensional liquid chromatography (LC) and tandem mass spectrometry (LC-MS/MS) analysis is emerging as a powerful methodology in the search for tumor biomarkers [@pone.0110736-Kakehashi1]. We previously reported that the side population (SP) cells are able to self-renew and produce non-SP cells, and that cancer cells in SP fractions possess high potential for tumorigenicity, distant metastasis[@pone.0110736-Nishii1], and chemoresistance[@pone.0110736-Yashiro1]. This suggests that SP cells of gastric cancer possess cancer stem cell-like properties. Therefore, the aim of this study was to detect a novel CSC marker(s) of gastric cancer by comparing the proteomes among parent cells and stem cell-like SP cells that have been known to possess a rich CSC population[@pone.0110736-Goodell1].

Materials and Methods {#s2}
=====================

Cell Cultures {#s2a}
-------------

Two gastric cancer cell lines, OCUM-2MD3 [@pone.0110736-Yashiro2] and OCUM-12 [@pone.0110736-Kato1], were used in this study. These cell lines were derived from diffuse-type gastric cancer. The culture condition was cultivated in Dulbecco\'s modified Eagle medium (DMEM; Nikken, Kyoto, Japan) with 10% heat-inactivated fetal calf serum (FCS; Life Technologies, Grand Island, NY), penicillin and streptomycin, and 0.5 mM sodium pyruvate, and incubated at 37°C. OCUM-12/SP and OCUM-2MD3/SP cell lines were SP cells that were evaluated by a flow cytometric analysis using Hoechst 33342 from their parent cell lines, OCUM-2MD3 and OCUM-12, respectively. Sorting was performed three times to establish a stable population of SP-enriched cells. After a three month incubation period post-sorting, OCUM-12/SP cells (6.5%) and OCUM-2MD3/SP cells (12.2%) still represented a high percentage of the SP fraction, compared to parent OCUM-12 (3.2%) and OCUM-2MD3 (6.3%) cells (**[Figure S1](#pone.0110736.s001){ref-type="supplementary-material"}**). Subsequently, these SP-enriched cells with a stable population were the cell lines used for the analysis, as previously reported [@pone.0110736-Hasegawa1].

Human Tissue Specimens and Patient Information {#s2b}
----------------------------------------------

Tissue specimens were obtained from 300 patients diagnosed with gastric cancer permitted operations at Osaka City University. [**Table 1**](#pone-0110736-t001){ref-type="table"} shows the clinicopathologic characteristics of the 300 gastric cancer patients. There were 208 male and 92 female patients, with the median age of 64 years (range, 28--85 years) at the time of operation. The diagnoses were confirmed by at least two people. Staging was determined in accordance with the Japanese classification of gastric carcinoma (14^th^ edition) [@pone.0110736-XX1]. This study was approved by the Osaka City University Ethics Committee (Osaka, Japan). Written informed consent from the donor was obtained for use of this sample in research.

10.1371/journal.pone.0110736.t001

###### Clinicopathological characteristics of 300 gastric cancer patients.
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  Clinicopathological features                             Number
  ------------------------------------- ----------------- --------
  Sex                                        Female          92
                                              male          208
  Age                                         \>60           97
                                               ≤60          203
  Macroscopic type                           Type-4          33
                                           Other types      267
  Tumor differentiation                  Intestinal type    154
                                          Diffuse type      146
  Depth of tumor invasion                      T1           137
                                               T2            32
                                               T3            24
                                               T4           107
  Lymph node metastasis                     Negative        165
                                            Positive        135
  Stage                                         I           146
                                               II            49
                                               III           44
                                               IV            61
  Total number of resected lymph node          ≤29          155
                                               ≥30          145
  Surgery type                                 D1           141
                                               D2           159

Protein Identification and Quantification by QSTAR Elite LC-MS/MS {#s2c}
-----------------------------------------------------------------

The cancer cells (60 µg each) were homogenized and then lysed using either 100 µL of T-PER lysis buffer (Thermo Scientific) or 500 µL of 9 M Urea, and 2% CHAPS lysis buffer with a protease inhibitor. Subsequently, the cell lysate was then treated by ultrasonication. After acetone precipitation, protein concentrations were measured by BCA Protein Assay (Pierce, IL, USA). Reduction, alkylation, digestion, and subsequent peptide labeling of 50 µg of protein for each sample were performed using the AB Sciex iTRAQ Reagent Multi-Plex Kit (AB Sciex, Concord, ON, Canada) [@pone.0110736-Chung1]. The iTRAQ-labeled samples were loaded onto an ICAT cation exchange cartridge (AB Sciex). The peptides were eluted as six fractions (1 mL KCL solution of 10, 50, 70, 100, 200, and 350 mM), and the supernatant of each was evaporated within a vacuum centrifuge. Samples were then desalted and concentrated using Sep-Pak Light C18 cartridges (Waters Corporation, Milford, MA), evaporated within a vacuum centrifuge, resuspended in 20 µL of 0.1% (v/v) formic acid, and subsequently applied onto QSTAR Elite LC-MS/MS. Each sample was run for 150 minutes. MS/MS data was searched against the Swiss Protein database (HUMAN) using ProteinPilot software (version 2.0, AB Sciex) with trypsin set as the digestion enzyme and methyl methanethiosulfinate as the cysteine modification. In order to remove redundant hits and comparative quantitation, the search results obtained were further processed by ProteinPilot software using the Paragon Algorithm. This resulted in the minimal set of justifiable identified proteins. All reported data was used with a 95% confidence cut-off limit. Relative quantitation of peptides was calculated as a ratio by dividing the iTRAQ reporter intensity. The ratios of peptides that support the existence of one protein were averaged for the relative protein quantitation. Thereafter, the ProteinPilot analysis and Ingenuity pathway analysis (IPA) (Ingenuity System, Mountain View, CA) were performed. After performing a Simple t-test on one of the calculated averaged protein ratios against 1 to assess the validity of the protein expression changes, a p-value was reported. Protein ratios with a p-value of less than 0.05 were considered reliable. It should be known that in 90% of the iTRAQ experimental runs done previously, the standard deviations of the protein ratios, which stem from technical variations, were reported to be less than 0.3. Therefore, expression changes greater than 1.2-fold or less than 0.8-fold of normalized expression levels were considered to be outside the range of technical variability. We also performed a non-labeled analysis, and detected the presence of proteins only within OCUM-12/SP cells and OCUM-2MD3/SP cells, but not within parent cells [@pone.0110736-Kakehashi2]. Each sample was run twice. The applied LC-MS/MS examination coupled with iTRAQ technology have been reported as a reliable quantitative method for protein expression, being even more sensitive than the western blot which depends on the type of applied antibodies [@pone.0110736-Ross1].

IPA and Selection of Candidate Proteins {#s2d}
---------------------------------------

The IPA database is primarily used in the field of proprietary ontology, containing up to 300,000 biological articles including genes, proteins, molecular and cellular processes. Therefore, IPA was employed for the analysis of protein molecular functions, localization. In addition, detailed information regarding the functions and cellular locations of the identified proteins was obtained. Based on the results of LC MS/MS and IPA analyses, proteins that were observed to be over-expressed in SP cell-lines, when compared to their corresponding frequency of expression in parent cell-lines, were selected as candidate biomarkers for SP cells of gastric cancer. The identification of networks of interacting proteins, as well as functional groups and pathways was generated by IPA, and the analysis depends on the previously characterized associations.

Quantitative Real-time Reverse Transcription-polymerase Chain Reaction (RT-PCR) {#s2e}
-------------------------------------------------------------------------------

Gastric cancer cells were cultured. And the total cellular RNA was extracted using RNeasy Mini Kit (QIAGEN, Carlsbad, CA). cDNA was prepared from 2 µg RNA using random primers (Invitrogen). To determine fold changes in each gene, RT-PCR was performed on the ABI Prism 7000 (Applied Biosystems, Foster City, CA), with commercially available gene expression assays (Applied Biosystems) for *RBBP6* (*retinoblastoma binding protein 6*; Hs00544663), *HSPA4* (*heat shock 70kDa protein 4*; Hs00382884), *HSPA9* (*heat shock 70 kDa protein 9*; Hs00269818), *GLG1* (Golgi glycoprotein 1; Hs00939452), *DCTPP1* (*dCTP pyrophosphatase 1*; Hs00225433), *VPS13A* (*vacuolar protein sorting 13 homolog A*; Hs00362891), *CK18 (keratin 18*; Hs028277483), *ALDOA (aldolase A*; Hs00605108), *CD44* (Hs01075862), *CD133* (Hs01009250) and *NANOG* (Hs02387400). GAPDH (SIGMA) was used as an internal standard to normalize mRNA levels. The threshold cycle (Ct) values were used to calculate the relative expression ratios between control and treated cells.

Western blot analysis {#s2f}
---------------------

Expression level of RBBP6 and ALDOA in cancer cells was examined as follows. Cell lysates were collected after different treatments. After the protein concentration of each sample was adjusted, electrophoresis was carried out using 10% Tris/Gly gels (Life Technologies, Carlsbad, CA). The protein bands obtained were transferred to an Immobilon-P Transfer membrane (Amersham, Aylesbury, UK). Then, the membrane was placed in PBS-T solution containing anti-RBBP6 (WH0005930M1, Sigma-aldrich, MO, USA), anti-ALDOA (HPA004177, ATLAS), and anti-β-actin (1∶300 dilution; Sigma-aldrich), and allowed to react at room temperature for 2 hours. The levels of specific proteins in each lysate were detected by enhanced chemiluminescence using ECL plus (Amersham) followed by autoradiography.

Small Interfering RNA Design {#s2g}
----------------------------

The sequences for *RBBP6* small interfering RNA (siRNA) are designed as follows: si*RBBP6* sense, 5′-GAAAGAAGAAUAUACUGAUtt-3′; antisense, 5′- AUCAGUAUAUUCUUCUUUCgt-3′, and nontargeting siRNA (negative-siRNA) was purchased from Ambion (Life Technologies, Carlsbad, CA).OCUM-12/SP and OCUM-2MD3/SP cells were prepared at 60% confluence in six-well dishes. The transfection mixture was prepared by adding 150 µL of Opti-MEM including 9 µL of Lipofectamine RNA iMAX Regant (Life Technologies) to 150 µL of Opti-MEM including 90 pmol of siRNA and incubating for 5 min at room temperature. Finally, the above transfection mixture was added to prepared six-well dish. Twenty-four hours after transfection, RT-PCR was performed.

Wound-healing Assay {#s2h}
-------------------

Cancer cells were cultured in 96-well plates (Essen Instruments, Birmingham, UK). After the cells reached semi-confluence, a wound was created in the cell monolayer with the 96-well by WoundMaker (Essen Bioscience, MI, USA). Scratched fields were taken pictured every 3 hours and was monitored with Incucyte Live-Cell Imaging System and software (Essen Instruments). The degree of cell migrations was analyzed 24 hours after wound treatment as a percentage of wound confluence. The mean of 4 fields was calculated as the sample value.

Invasion Assay {#s2i}
--------------

We used the chemotaxicell chambers (Kubota, Osaka, Japan) with a 12-µm pore membrane filter coated with 50-µg Matrigel (Collaborative Research Co., Bedford, MA). The chamber (upper component) was placed in a 24-well culture plate (lower component). Gastric cancer cells were re-suspended to a final concentration of 5×10^3^ cells/mL. Next, 500-µL lower components. After incubation for 48 h, cancer cells on the upper surface of the membrane were removed by wiping and stained with hematoxylin. Cancer cells that invaded through a filter coated with Matrigel into the lower membrane were manually counted under a microscope at ×200 magnification. Six randomly chosen fields were counted for each assay. The mean of four fields was calculated as the sample value. For each group, the culture was done in triplicate.

Validation of Protein Expression by Immunohistochemistry {#s2j}
--------------------------------------------------------

Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue samples that were deparaffinized in xylene and dehydrated through graded ethanol. The sections were heated for 10 minutes at 105°C by autoclave in Target Retrieval Solution (DAKO). The samples were subsequently incubated with 3% hydrogen peroxide to block endogenous peroxidase activity. The following antibodies were used in the immunohistochemical process: anti-RBBP6 (retinoblastoma binding protein 6; WH0005930M1, 6∶1000; Sigma-Aldrich), anti-GLG1 (Golgi glycoprotein 1; HPA010815, 1∶80; ATLAS), anti-VPS13A (vacuolar protein sorting 13 homolog A; NBP1-85642, 1∶500; Novus Biologicals), anti-ALDOA (aldolase A, fructose-bisphosphate; HPA004177, 1∶400; ATLAS), anti-DCTPP1 (dCTP pyrophosphatase 1; HPA002832, 1∶200; ATLAS), anti-HSPA9 (heat shock 70 kDa protein 9; HPA000898, 1∶200; ATLAS), anti-HSPA4 (heat shock 70kDa protein 4; HPA010023, 1∶200; ATLAS), and anti-KRT18 (keratin 18; ab668, 1∶500; Abcam). The samples were incubated with each antibody overnight at approximately 4°C. Thereafter, samples were incubated in appropriated immunoglobulin G for 10 minutes, followed by three washes with PBS. All samples were then treated with streptavidin-peroxidase reagent, and incubated in PBS diaminobenzidine and 1% hydrogen peroxide (vol/vol), followed by counterstaining with Mayer\'s hematoxylin.

Immunohistochemical Evaluation {#s2k}
------------------------------

RBBP6, GLG1, VPS13A, DCTPP1, HSPA9, HSPA4, ALDOA, and KRT18 expression levels were evaluated by both intensity of staining and proportion of stained tumor cells. The staining intensity was scored on a scale of 0-3 (0 = no, 1 =  mild, 2 =  moderate, 3 =  intense). Staining proportions were scored on a scale of 0--4 (the percentage was different with each antibody) based on the percentage of positively stained cells. Therefore, the final staining score, which was calculated as a multiple of the staining intensity score and the staining proportion score, would be on a scale of 0--12. Expression levels of DCTPP1 were considered positive when it received a score of 3. Expression levels of HSPA4 were considered positive when it received a score of 6. Expression levels of ALDOA, KRT18, VPS13A, and GLG1 were considered positive when each received a score of 8. RBBP6, the evaluation of which only the staining proportion score was used for calculation, was considered positive when it received a score of 3. HSPA9, the evaluation of which only the staining intensity score was used for calculation, was considered positive when it received a score of 3. All evaluations were made by two observers who were unaware of clinical data and outcome. When a discrepant evaluation between the two independent observers was found, the slides were rechecked and reevaluated after discussion.

Statistical Analysis {#s2l}
--------------------

The SPSS software program (SPSS Japan, Tokyo, Japan) was used for data analysis. Statistical significance of the associations between the expression of proteins and the various clinicopathological variables, including age, sex, macroscopic type, tumor differentiation, total number of resected lymph node, and type of surgery (D1 or D2 gastrectomy) was evaluated using Fisher\'s and Chi-squared tests. Survival curves were calculated from the day of surgery to the time of death or to the last follow-up observation using the Kaplan-Meier Method. Additionally, any differences between survival curves were assessed using the Log-rank Test. Multivariate analyses were performed according to the Cox Regression Model to determine the associations between clinicopathological variables and mortality. P-values of \<0.05 was considered statistically significant.

Results {#s3}
=======

The stemness of gastric cancer cell lines {#s3a}
-----------------------------------------

The percentages of SP cells were higher in the OCUM-12/SP and OCUM-2MD3/SP cells than in their parent OCUM-12 and OCUM-2MD3 cells (**[Figure S1](#pone.0110736.s001){ref-type="supplementary-material"}**). Cancer stem cell markers of SP cells, OCUM-12/SP and OCUM-2MD3/SP, such as CD44, CD133, and NANOG, were analyzed by RT-PCR. The expression level of these markers was significantly increased in both SP cell lines, in comparison with their parent cell lines (**[Figure S2](#pone.0110736.s002){ref-type="supplementary-material"}**). The number of spheroid colony was significantly higher in both OCUM-12/SP and OCUM-2MD3/SP cells than their parent OCUM-12 and OCUM-2MD3 cells (data not shown).

Detection of Candidate Proteins {#s3b}
-------------------------------

We investigated whether proteins were differentially or independently expressed in SP cells, and compared our findings to those of their parent cells using QSTAR Elite LC-MS/MS. In analyzing biological processes, and with a 95% confidence cut-off limit and p\<0.05, we identified that proteins were indeed differentially expressed. The results of these findings are presented in [**Figure 1**](#pone-0110736-g001){ref-type="fig"}. Most of the proteins were over-expressed in the cytoplasm of tumor cells ([**Figure 1A**](#pone-0110736-g001){ref-type="fig"}). The P value included in the ingenuity analysis is stated in **[Table S1](#pone.0110736.s004){ref-type="supplementary-material"}**. These proteins were determined to be related to cellular processes, such as cell death, metabolism, cellular organization, DNA metabolism, protein degradation, and processing of RNA ([**Figure 1B**](#pone-0110736-g001){ref-type="fig"}). The top canonical pathways associated with these targets and identified by IPA are shown in **[Table S2](#pone.0110736.s005){ref-type="supplementary-material"}**.

![Ingenuity Pathway Analysis (IPA) of Proteins Expressed in SP Cells.\
(A) Localization; (B) Biological processes of identified proteins. We categorized the proteins based on their functional assignments using Ingenuity Pathway Analysis. The molecular functions reported include cell death, metabolism, cellular organization, metabolism of DNA, protein degradation, processing of RNA, production of reactive oxygen species, nitric oxide, molecular transport, cell cycle, folding protein, and cellular movement. % = 100 X number of identified proteins/all 932 proteins analyzed. (C), A Venn diagram confer to [Table 2](#pone-0110736-t002){ref-type="table"}. Forty proteins were significantly increased in OCUM-12/SP cells compared to their parent OCUM-12 cells. Thirty-five proteins were significantly increased in OCUM-2MD3/SP cells compared to their parent OCUM-2MD3cells. Eight candidate proteins, RBBP6, HSPA4, HSPA9, GLG1, DCTPP1, VPS13A, CK18 and ALDOA, overlap in both OCUM-12/SP and OCUM-2MD3/SP cells. (D), mRNA expression. RT-PCR analysis indicated that the expression level of *RBBP6, HSPA4, DCTPP1, HSPA9, VPS13A, ALDOA, GLG1*, and *CK18* was high in OCUM-12/SP (9.15 fold, 9.36 fold, 4.14 fold, 7.80 fold, 2.08 fold, 1.46 fold, 3.44 fold, and 1.99 fold, respectively) and OCUM-2MD3/SP (6.15 fold, 1.71 fold, 2.33 fold, 2.30 fold, 2.03 fold, 1.32 fold, 1.35 fold, and 1.31 fold, respectively), in compared with the control of parent OCUM-12 and OCUM-2MD3. (E), Correlation of Signaling Pathways between RBBP6 and Differentially-Expressed Proteins in CSC-like SP cells. RBBP6 is over-expressed (red) in CSC-like SP cells (OCUM-12/SP cells and OCUM-2MD3/SP cells). Hsp90, HSPA4, and TAGLN2 (pink) up-regulated in CSC-like SP cells were associated with the RBBP6 signaling pathway.](pone.0110736.g001){#pone-0110736-g001}

When compared to their corresponding parent cells, 40 proteins were up-regulated in OCUM-12/SP, and 35 proteins were up-regulated in OCUM-2MD3/SP. Among these proteins, eight were up-regulated in both OCUM-12/SP cells and OCUM-2MD3/SP cells, whereas no such association was observed between their corresponding parent cells ([**Table 2**](#pone-0110736-t002){ref-type="table"} **and** [**Figure 1C**](#pone-0110736-g001){ref-type="fig"}). Of these eight proteins, the three proteins, RBBP6, GLG1, and VPS13A, were independently detected in both SP cell lines, but not in their corresponding parent cells. The five proteins, DCTPP1, HSPA9, HSPA4, ALDOA, and KRT18, were significantly over-expressed by at least 1.2-fold in both SP cells when compared to their corresponding parent cells.

10.1371/journal.pone.0110736.t002

###### Proteins increased in both OCUM-12/SP and OCUM-2MD3/SP cells compared to their parent cells detected by QSTAR Elite LC/MS/MS.
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  Symbol                                                                                   Protein Name                                                                 GI Number   UniProt/Swiss-Prot   Ratio[a](#nt101){ref-type="table-fn"}   p value    Loca-tion[c](#nt103){ref-type="table-fn"}   Type[d](#nt104){ref-type="table-fn"}
  -------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ----------- -------------------- --------------------------------------- ---------- ------------------------------------------- --------------------------------------
  OCUM-12/SP                                                                                                                                                                                                          OCUM-12/SP                                                                       
  RBBP6                                                                          retinoblastoma binding protein 6                                                       74762440          Q7Z6E9           ↑[b](#nt102){ref-type="table-fn"}        NA                          N                                        En
  GLG1                                                                                 golgi glycoprotein 1                                                             218512060         Q92896                           ↑                        NA                          C                                        O
  VPS13A                                                               vacuolar protein sorting 13 homolog A (S. cerevisiae)                                            71152975          Q96RL7                           ↑                        NA                          C                                        Tp
  DCTPP1                                                                              dCTP pyrophosphatase 1                                                            74733624          Q9H773                         2.258                    0.0206                        C                                        En
  HSPA9                                                                       heat shock 70 kDa protein 9 (mortalin)                                                    21264428          P38646                         1.511                    0.0006                        C                                        O
  HSPA4                                                                             heat shock 70 kDa protein 4                                                         206729934         P34932                         1.187                    0.009                         C                                        O
  ALDOA                                                                          aldolase A, fructose-bisphosphate                                                       113606           P04075                         1.588                   \<0.0001                       C                                        En
  KRT18                                                                                     keratin 18                                                                   125083           P05783                         1.329                    0.0003                        C                                        O
  NAMPT                                                                       nicotinamide phosphoribosyltransferase                                                     1172027          Q4LAY1                         1.805                      0                          ES                                     cytokine
  ACO2 (includes EG:11429)                                                          aconitase 2, mitochondrial                                                           6686275          Q99798                         1.549                    0.0312                        C                                        En
  AKR1B1                                                            aldo-keto reductase family 1, member B1 (aldose reductase)                                           113596           P15121                         1.906                    0.0021                        C                                        En
  AKR1B10                                                           aldo-keto reductase family 1, member B10 (aldose reductase)                                         20531983          O83905                         1.946                      0                           C                                        En
  CBR1                                                                                 carbonyl reductase 1                                                              118519           P16152                         1.472                    0.0456                        C                                        En
  GAPDH                                                                      glyceraldehyde-3-phosphate dehydrogenase                                                    120649           P04406                         1.095                      0                           C                                        En
  GART                              phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase           131616           P22102                         1.254                    0.036                         C                                        En
  GSTM3                                                                       glutathione S-transferase mu 3 (brain)                                                    21264423          P21266                         1.304                    0.0018                        C                                        En
  HSP90AA1                                                         heat shock protein 90 kDa alpha (cytosolic), class A member 1                                        92090606          P07900                         1.25                     0.0022                        C                                        En
  HSP90AB1                                                         heat shock protein 90 kDa alpha (cytosolic), class B member 1                                        17865718          P08238                         1.487                    0.0068                        C                                        En
  HSPD1                                                                      heat shock 60 kDa protein 1 (chaperonin)                                                    129379           P10809                         1.569                      0                           C                                        En
  MTHFD1                      methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase    115206           P11586                         1.212                    0.0196                        C                                        En
  PRDX6                                                                                   peroxiredoxin 6                                                                1718024          P30041                         1.345                    0.015                         C                                        En
  TALDO1                                                                                  transaldolase 1                                                                6648092          P37837                         1.202                    0.0044                        C                                        En
  UGDH                                                                              UDP-glucose 6-dehydrogenase                                                          6175086          B1YLK1                         1.198                    0.0318                        N                                        En
  PFKP                                                                             phosphofructokinase, platelet                                                         1346355          Q01813                         1.338                    0.0019                        C                                        K
  PKM2                                                                                pyruvate kinase, muscle                                                           20178296          P14618                         1.275                      0                           C                                        K
  ACTN4                                                                                  actinin, alpha 4                                                               13123943          I4AQQ0                         1.208                    0.0011                        C                                        O
  CANX                                                                                       calnexin                                                                    543920           P27824                         1.612                    0.0005                        C                                        O
  HSPA2                                                                             heat shock 70 kDa protein 2                                                          1708307          P54652                         1.396                    0.0358                        C                                        O
  RPL6                                                                                 ribosomal protein L6                                                              1350762          Q02878                         1.368                    0.0027                        C                                        O
  TAGLN2                                                                                   transgelin 2                                                                  586000           P37802                         1.239                    0.0134                        C                                        O
  WDR1                                                                                  WD repeat domain 1                                                              12643636          G2TFZ5                         1.358                    0.0381                       ES                                        O
  PTMA                                                                                  prothymosin, alpha                                                               135834           P06454                         1.156                    0.0401                        N                                        O
  PPP2R1A                                                               protein phosphatase 2, regulatory subunit A, alpha                                              143811355         P30153                         1.439                    0.0003                        C                                   phosphatase
  SQSTM1                                                                                  sequestosome 1                                                                74735628          Q13501                         1.877                    0.0038                        C                                        TR
  EIF3B                                                                eukaryotic translation initiation factor 3, subunit B                                            218512094         P55884                         1.234                    0.0229                        C                                        TR
  RPSA                                                                                 ribosomal protein SA                                                              125969           P08865                         1.31                     0.0017                        C                                        TR
  ATP2A1                                                             ATPase, Ca2+ transporting, cardiac muscle, fast twitch 1                                           12643544          G2TF52                         1.058                    0.0305                        C                                        Tp
  ATP5B                                                      ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide                                   114549           P06576                         1.594                    0.0111                        C                                        Tp
  ETFA                                                                   electron-transfer-flavoprotein, alpha polypeptide                                               119636           P13804                         1.473                    0.0003                        C                                        Tp
  KPNB1                                                                            karyopherin (importin) beta 1                                                        20981701          Q14974                         1.188                    0.0397                        N                                        Tp
  OCUM-2MD3/SP                                                                                                                                                                                                    OCUM-2MD3/SP ratio                                                                   
  RBBP6                                                                          retinoblastoma binding protein 6                                                       74762440          Q7Z6E9                           ↑                        NA                          N                                        En
  GLG1                                                                                 golgi glycoprotein 1                                                             218512060         Q92896                           ↑                        NA                          C                                        O
  VPS13A                                                               vacuolar protein sorting 13 homolog A (S. cerevisiae)                                            71152975          Q96RL7                           ↑                        NA                          C                                        Tp
  DCTPP1                                                                              dCTP pyrophosphatase 1                                                            74733624          Q9H773                         1.467                      0                           C                                        En
  HSPA9                                                                       heat shock 70 kDa protein 9 (mortalin)                                                    21264428          P38646                         1.778                    0.0005                        C                                        O
  HSPA4                                                                             heat shock 70 kDa protein 4                                                         206729934         P34932                         1.27                      0.01                         C                                        O
  ALDOA                                                                          aldolase A, fructose-bisphosphate                                                       113606           P04075                         1.533                    0.035                         C                                        En
  KRT18                                                                                     keratin 18                                                                   125083           P05783                         1.618                    0.0066                        C                                        O
  MDH2 (includes EG:17448)                                                  malate dehydrogenase 2, NAD (mitochondrial)                                                 215274114         P40926                         1.604                    0.0244                        C                                        En
  PRDX1                                                                                   peroxiredoxin 1                                                                548453           Q06830                         1.334                    0.0003                        C                                        En
  DLST                                                   dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex)                               206729909         P36957                         1.277                    0.0483                        C                                        En
  PDIA4                                                                   protein disulfide isomerase family A, member 4                                                 119530           P13667                         1.494                    0.0353                        C                                        En
  PYGB                                                                            phosphorylase, glycogen; brain                                                        20178317          P11216                         1.87                     0.0071                        C                                        En
  NARS                                                                              asparaginyl-tRNA synthetase                                                          3915059          O53857                         2.239                    0.0089                        C                                        En
  UBA1                                                                      ubiquitin-like modifier activating enzyme 1                                                 24418865          P22314                         1.353                    0.0467                        C                                        En
  P4HB                                                                        prolyl 4-hydroxylase, beta polypeptide                                                     2507460          P07237                         1.852                    0.043                         C                                        En
  LDHA                                                                                lactate dehydrogenase A                                                            126047           P00338                         1.373                    0.0014                        C                                        En
  PPIB                                                                      peptidylprolyl isomerase B (cyclophilin B)                                                  215273869         P23284                         1.783                    0.0112                        C                                        En
  GPI                                                                              glucose-6-phosphate isomerase                                                        17380385          P06744                         2.023                    0.0027                       ES                                        En
  SSB                                                                       Sjogren syndrome antigen B (autoantigen La)                                                  125985           P05455                         1.501                    0.0222                        N                                        En
  HDGF                                                                            hepatoma-derived growth factor                                                         1708157          P51858                         2.537                    0.0468                       ES                                  growth factor
  HYOU1                                                                               hypoxia up-regulated 1                                                            10720185          Q9Y4L1                         1.643                    0.0005                        C                                        O
  HSP90B1                                                                heat shock protein 90 kDa beta (Grp94), member 1                                                119360           P14625                         3.233                    0.0003                        C                                        O
  AGR2                                                                     anterior gradient 2 homolog (Xenopus laevis)                                                 67462105          O95994                         2.172                    0.0107                       ES                                        O
  HIST1H1E                                                                            histone cluster 1, H1e                                                             121919           P10412                         1.562                    0.0353                        N                                        O
  HNRNPA2B1                                                                heterogeneous nuclear ribonucleoprotein A2/B1                                                 133257           P22626                         1.634                    0.0059                        N                                        O
  HNRNPF                                                                     heterogeneous nuclear ribonucleoprotein F                                                   1710628          P52597                         1.445                    0.0393                        N                                        O
  MARCKS                                                               myristoylated alanine-rich protein kinase C substrate                                            76803798          P29966                         2.018                      0                          PM                                        O
  CALR                                                                                     calreticulin                                                                  117501           P27797                         4.181                      0                           C                                        TR
  YBX1                                                                                Y box binding protein 1                                                           54040030          P67809                         1.401                    0.0297                        N                                        TR
  NPM1                                                                nucleophosmin (nucleolar phosphoprotein B23, numatrin)                                             114762           P06748                         1.32                     0.0201                        N                                        TR
  HNRNPD                                             heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 37kDa)                           13124489          Q14103                         1.483                    0.0068                        N                                        TR
  TUFM                                                                    Tu translation elongation factor, mitochondrial                                                1706611          P49411                         2.205                    0.0143                        C                                        TR
  EIF2S1                                                        eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa                                       124200           P05198                         1.474                      0                           C                                        TR
  HNRNPU                                                     heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A)                                   254763463         Q00839                         1.637                    0.0252                        N                                        Tp

ratio, OCUM-12/SP ratio: OCUM-12/SP cell compared with parent OCUM-12 cell. OCUM-2MD3/SP ratio: OCUM-2MD3/SP cell compared with parent OCUM-2MD3 cell.

↑, proteins expressed only in SP cells but not parent cells.

Location: C, cytoplasm; PM, plasma membrane; ES, extracellular space; N, nucleus.

Type: En, enzyme; K, kinase; Tp, transporter; O, other; TR, transcriptional regulator.

NA, not available.

The mRNA expression level of these 8 candidate molecules, *RBBP6, HSPA4, DCTPP1, HSPA9, VPS13A, ALDOA, GLG1*, and *CK18* was increased in OCUM-12/SP (9.15 fold, 9.36 fold, 4.14 fold, 7.80 fold, 2.08 fold, 1.46 fold, 3.44 fold, and 1.99 fold, respectively) and OCUM-2MD3/SP (6.15 fold, 1.71 fold, 2.33 fold, 2.30 fold, 2.03 fold, 1.32 fold, 1.35 fold, and 1.31 fold, respectively) cells, in comparison with those of the control of parent OCUM-12 and OCUM-2MD3 cells ([**Figure 1D**](#pone-0110736-g001){ref-type="fig"}). Western blot analysis indicated that the expression level of RBBP6 and ALDOA was high in CUM-12/SP and OCUM-2MD3/SP cells, in comparison with that OCUM-12 and OCUM-2MD3 cells (**[Figure S3](#pone.0110736.s003){ref-type="supplementary-material"}**).

The network presented in [**Figure 1E**](#pone-0110736-g001){ref-type="fig"} was generated by IPA, and the analysis depends on the previously characterized and reported protein interactions. Thus, RBBP6, which was observed to be over-expressed in CSC-like SP cells, OCUM-12/SP cells and OCUM-2MD3/SP cells, was directly related to HSPA4 and Rb, and indirectly associated with Hsp90 and TAGLN2. HSPA4, Hsp90 and TAGLN2 were also found to be up-regulated in CSC-like SP cells.

Effect of siRBBP6 transfection on the migration and invasive abilities of gastric cancer cells {#s3c}
----------------------------------------------------------------------------------------------

[**Figure 2A**](#pone-0110736-g002){ref-type="fig"} shows that si*RBBP6* transfection significantly decreased mRNA expression level of both SP cell lines (OCUM-12/SP was 12%, p\<0.01, OCUM-2MD3/SP was 2.5%. p\<0.01), in compared with that of negative-siRNA transfection. *RBBP6* siRNA knockdown significantly decreased the invasion ([**Figure 2B**](#pone-0110736-g002){ref-type="fig"}) and migration activity ([**Figure 2C**](#pone-0110736-g002){ref-type="fig"}) of both SP cells.

![*siRBBP6* transfection into gastric cancer cells.\
(A), OCUM-12/SP and OCUM-2MD3/SP showed higher level of *RBBP6* mRNA expression than their parent cells, OCUM-12 and OCUM-2MD3. RBBP6 expression in OCUM-12/SP and OCUM-2MD3/SP cells was effectively downregulated by si*RBBP6* transfection. (B), Representative images of invading OCUM-12/SP cells showed the number of cancer cells invading the pore membrane filter was decreased by *RBBP6* siRNA treatment. si*RBBP6* transfection for OCUM12/SP cells significantly inhibited the invasion abilities. Data are presented as the mean and SD (error bars) of four experiments. \* *p*\<0.05, \*\* *p*\<0.01. (C), si*RBBP6* treatment for OCUM12/SP and OCUM-2MD3/SP cells significantly inhibited the migration abilities, in comparison with that of the control of *negative-siRNA* treatment. Data are presented as the mean and SD (error bars) of four experiments. \* *p*\<0.05, \*\* *p*\<0.01.](pone.0110736.g002){#pone-0110736-g002}

Immunohistochemical Assessment of Candidate Proteins and their Association with Clinicopathological Features {#s3d}
------------------------------------------------------------------------------------------------------------

RBBP6, DCTPP1, and HSPA9 were observed to be primarily expressed in the cytoplasm and nuclei of gastric cancer cells. GLG1, VPS13A, HSPA9, HSPA4, ALDOA, and KRT18 were observed to be primarily expressed in the cytoplasm ([**Figure 3A**](#pone-0110736-g003){ref-type="fig"}). In normal epithelial cells, RBBP6, GLG1, VPS13A, DCTPP1, and HSPA9 expression were found some cells in the epithelial gland. KRT18 were expressed in most epithelial cells. HSPA4 and ALDOA expression was not found in normal cells. BBP6, DCTPP1, and HSPA9 were expressed in the cytoplasm and nuclei of normal epithelial cells. GLG1, VPS13A, HSPA9, and KRT18 were observed in the cytoplasm of epithelial cells ([**Figure 3B**](#pone-0110736-g003){ref-type="fig"}).

![Immunohistochemical Determination.\
(a) Expression in cancer cells. RBBP6, DCTPP1, and HSPA9 expression were observed primarily in the cytoplasm and nucleus. GLG1, VPS13A, HSPA4, ALDOA, and KRT18 were expressed in the cytoplasm. (b), Expression in epithelial cells. RBBP6, GLG1, VPS13A, DCTPP1, and HSPA9 expression were found some cells in the epithelial gland. KRT18 were expressed in most epithelial cells. HSPA4 and ALDOA expression was not found in normal cells.](pone.0110736.g003){#pone-0110736-g003}

We explored the association between the expression level of the eight candidate proteins and the clinicopathological features. Number of cases to each score for the eight targets was shown in **[Table S3](#pone.0110736.s006){ref-type="supplementary-material"}**. These eight proteins were determined to be associated with potentially malignant processes, such as distant metastasis, lymph node (LN) metastasis, invasion depth, or stage advancement ([**Table 3**](#pone-0110736-t003){ref-type="table"}). The calculated p-values were as follows: RBBP6 was significantly associated with invasion depth (p\<0.001), LN metastasis (p\<0.001), distant metastasis (p = 0.013), and clinical stage (p\<0.001); GLG1 was significantly associated with only distant metastasis (p = 0.045). VPS13A was significantly associated with invasion depth (p = 0.005), LN metastasis (p\<0.001), and stage advancement (p = 0.005); DCTPP1 was significantly associated with invasion depth (p\<0.001), LN metastasis (p\<0.001), distant metastasis (p\<0.001), and stage advancement (p\<0.001); HSPA9 was significantly associated with invasion depth (p\<0.001), LN metastasis (p\<0.001), and stage advancement (p\<0.001); HSPA4 was significantly associated with invasion depth (p\<0.001), LN metastasis (p\<0.001), distant metastasis (p = 0.007), and stage advancement (p\<0.001); ALDOA was significantly associated with invasion depth (p = 0.034), LN metastasis (p = 0.004), and stage advancement (p = 0.029); and KRT18 was significantly associated with invasion depth (p = 0.001), LN metastasis (p = 0.001), distant metastasis (p = 0.034), and stage advancement (p = 0.004).

10.1371/journal.pone.0110736.t003

###### Correlation between proteins expression and clinicopathological variables.

![](pone.0110736.t003){#pone-0110736-t003-3}

  Factors                  RBBP6   GLG1    VPS13A    DCTPP1                                                            
  ----------------------- ------- ------- --------- -------- ------- ------- ------- ------- --------- ------- ------- ---------
  T category                                                                                                           
  T2-T4                     102     58     \<0.001     46      115    0.045    93      68      0.005     105     57     \<0.001
                           (64%)   (36%)             (29%)    (71%)           (58%)   (42%)             (65%)   (35%)  
  T1                        49      85                 24      106             56      79                35      102   
                           (37%)   (63%)             (19%)    (81%)           (42%)   (58%)             (65%)   (35%)  
  Lymph node metastasis                                                                                                
  positive                  86      44     \<0.001     34      97     0.493    81      50     \<0.001    88      44     \<0.001
                           (66%)   (34%)             (26%)    (74%)           (62%)   (38%)             (67%)   (33%)  
  negative                  65      99                 36      124             68      97                52      115   
                           (40%)   (60%)             (23%)    (77%)           (41%)   (59%)             (31%)   (69%)  
  Distant metastasis                                                                                                   
  positive                  40      21      0.013      15      46     0.912    35      26      0.217     41      20     \<0.001
                           (66%)   (34%)             (25%)    (75%)           (57%)   (43%)             (67%)   (33%)  
  negative                  111     122                55      175             114     121               99      139   
                           (48%)   (52%)             (24%)    (76%)           (48%)   (52%)             (42%)   (58%)  
  Clinical Stage                                                                                                       
  I                         55      89     \<0.001     26      114    0.116    58      87      0.005     44      103    \<0.001
                           (38%)   (62%)             (19%)    (81%)           (40%)   (60%)             (30%)   (70%)  
  II                        23      24                 14      33              31      16                26      22    
                           (49%)   (51%)             (30%)    (70%)           (66%)   (34%)             (54%)   (46%)  
  III                       33       9                 15      28              25      18                29      14    
                           (79%)   (21%)             (35%)    (65%)           (58%)   (42%)             (67%)   (33%)  
  IV                        40      21                 15      46              35      26                41      20    
                           (66%)   (34%)             (25%)    (75%)           (57%)   (43%)             (67%)   (33%)  

  Factors                  HSPA9   HSPA4    ALDOA    KRT18                                                            
  ----------------------- ------- ------- --------- ------- ------- --------- ------- ------- ------- ------- ------- -------
  T category                                                                                                          
  T2-T4                     96      65     \<0.001    109     52     \<0.001    50      111    0.034    84      76     0.001
                           (60%)   (40%)             (68%)   (32%)             (31%)   (69%)           (53%)   (47%)  
  T1                        47      86                60      76                27      107             43      87    
                           (35%)   (65%)             (44%)   (56%)             (20%)   (80%)           (33%)   (67%)  
  Lymph node metastasis                                                                                               
  positive                  79      52     \<0.001    97      34     \<0.001    45      86     0.004    72      59     0.001
                           (60%)   (40%)             (74%)   (26%)             (34%)   (66%)           (55%)   (45%)  
  negative                  64      99                72      94                32      132             55      104   
                           (39%)   (61%)             (43%)   (57%)             (20%)   (80%)           (35%)   (65%)  
  Distant metastasis                                                                                                  
  positive                  36      25      0.069     44      17      0.007     21      40     0.096    34      27     0.034
                           (59%)   (41%)             (72%)   (28%)             (34%)   (66%)           (56%)   (44%)  
  negative                  107     126               125     111               56      178             93      136   
                           (46%)   (54%)             (47%)   (53%)             (24%)   (76%)           (44%)   (56%)  
  Clinical Stage                                                                                                      
  I                         49      94     \<0.001    60      86     \<0.001    27      117    0.029    48      91     0.004
                           (34%)   (66%)             (41%)   (59%)             (19%)   (81%)           (35%)   (65%)  
  II                        31      16                32      15                13      34              19      28    
                           (66%)   (34%)             (68%)   (32%)             (28%)   (72%)           (40%)   (60%)  
  III                       27      16                33      10                16      27              26      17    
                           (63%)   (37%)             (77%)   (23%)             (37%)   (63%)           (60%)   (40%)  
  IV                        36      25                44      17                21      40              34      27    
                           (59%)   (41%)             (72%)   (28%)             (34%)   (66%)           (56%)   (44%)  

Prognosis {#s3e}
---------

The Kaplan-Meier plots suggested that of the eight over-expressed proteins, RBBP6, DCTPP1, HSPA4, and ALDOA, were significantly associated with poor survival in all patients ([**Figure 4**](#pone-0110736-g004){ref-type="fig"}). The cumulative five-year overall survival rate of RBBP6-positive cases (61%) was significantly less (p = 0.002) than that of RBBP6-negative cases (78%). Moreover, in patients at stage III, the overall survival rate of RBBP6-positive cases was significantly less (p = 0.034) than that of RBBP6-negative cases. The prognosis of patients with DCTPP1-positive tumors (63%) was significantly poorer (p = 0.016) than that of DCTPP1-negative tumors (75%). The five-year overall survival rate of HSPA4-positive cases (66%) was significantly less (p = 0.047) than that of HSPA4-negative cases (75%). The five-year overall survival rate of ALDOA-positive tumors exhibiting over-expression (61%) was significantly poorer (p = 0.043) than that of ALDOA-negative tumors (72%). In contrast, no significant correlations were observed between other proteins and patient survival. Following univariate analysis, RBBP6, DCTPP1, HSPA4, and ALDOA expression levels were significantly associated with poor prognosis in 300 gastric cancer patients ([**Table 4**](#pone-0110736-t004){ref-type="table"}). In addition, macroscopic type (type 4), histological type (diffuse), T category (T2-4), vessel invasion, infiltration pattern (INF b, c), peritoneal metastasis, and LN metastasis were determined to be significantly associated with a poor prognosis. Multivariate analysis was performed using the Cox Proportional Hazards Model for all significant variables in the univariate analysis. Upon analysis completion, RBBP6 expression (p = 0.023), Borrmann type 4 (p\<0.001), peritoneum positive (p = 0.001), LN metastasis (p = 0.003), and hepatic metastasis (p = 0.001) were confirmed as independent factors correlated with survival ([**Table 3**](#pone-0110736-t003){ref-type="table"}). Of the eight proteins, RBBP6 expression was an independent prognostic factor.

![Overall Survival of Patients with Gastric Cancer.\
The overall survival of patients with gastric cancer in relation to the expression of RBBP6, GLG1, VPS13A, DCTPP1, HSPA9, HSPA4, ALDOA, and KRT18. The prognosis of patients with RBBP6, DCTPP1, HSPA4, and ALDOA expression was significantly poorer than those without expression in gastric cancer cases. The overall survival rate of RBBP6-positive cases was significantly less than that of RBBP6-negative cases in patients at stage III. In contrast, no significant correlations were observed between other proteins and patient survival.](pone.0110736.g004){#pone-0110736-g004}

10.1371/journal.pone.0110736.t004

###### Univariate and multivariate analyses with respect to survival.

![](pone.0110736.t004){#pone-0110736-t004-4}

  Clinicopathological features           Univariate analysis   Multivariate analysis                                    
  ------------------------------------- --------------------- ----------------------- --------- ------- --------------- ---------
  RBBP6                                                                                                                 
  positive vs negative                          1.964              1.275--3.025         0.002    1.770   1.080--2.901     0.023
  GLG1                                                                                                                  
  positive vs negative                          1.391              0.885--2.186         0.152                           
  VPS13A                                                                                                                
  positive vs negative                          1.145              0.885--2.186         0.521                           
  DCTPP1                                                                                                                
  positive vs negative                          1.661              1.096--2.516         0.017    0.902   0.558--1.458     0.674
  HSPA9                                                                                                                 
  positive vs negative                          0.983              0.747--1.295         0.905                           
  HSPA4                                                                                                                 
  positive vs negative                          1.544              1.002--2.378         0.049    0.929   0.549--1.571     0.784
  ALDOA                                                                                                                 
  positive vs negative                          1.563              1.010--2.421         0.045    1.454   0.866--2.442     0.156
  KRT18                                                                                                                 
  positive vs negative                          1.390              0.919--2.101         0.119                           
  Age                                                                                                                   
  \>60 vs \<60                                  1.424              0.894--2.268         0.137                           
  Sex                                                                                                                   
   Male vs female                               1.065              0.680--1.667         0.785                           
  Macroscopic type                                                                                                      
   Type4 vs Other types                         9.084              5.701--14.476       \<0.001   4.894   2.687--8.914    \<0.001
  Tumor differentiation                                                                                                 
  diffuse vs intestinal                         1.647              1.088--2.500         0.018    1.155   0.679--1.965     0.595
  T category                                                                                                            
  T2-4 vs T1                                    4.479              2.674--7.504        \<0.001   1.187   0.568--2.479     0.648
  Vessel invasion                                                                                                       
  positive vs negative                          3.070              1.967--4.793        \<0.001   0.961   0.559--1.653     0.886
  INF[a](#nt106){ref-type="table-fn"}                                                                                   
   c vs a & b                                   1.782              1.160--2.737         0.008    0.923   0.512--1.666     0.791
  Hepatic metastasis                                                                                                    
  positive vs negative                          7.776              3.369--17.950       \<0.001   4.927   1.953--12.429    0.001
  Peritoneal metastasis                                                                                                 
  positive vs negative                          8.209              4.734--14.236       \<0.001   3.043   1.600--5.789     0.001
  Lymph node metastasis                                                                                                 
  positive vs negative                          6.315              3.841--10.384       \<0.001   2.848   1.419--5.717     0.003
  Total number of resected lymph node                                                                                   
   \<29 vs\>30                                  0.903              0.600--1.359         0.626                           
  Surgery type                                                                                                          
   D2 vs D1                                     1.886              0.589--1.333         0.886                           

NF; Infiltration pattern of tumor. The predominant pattern of infiltrating growth into the surrounding tissue is classified as follows; INF a: The tumor shows expanding growth and a distinct border with the surrounding tissue. INF b: This category is between INF a and INF b. INF c: The tumor shows infiltrating growth and an indistinct border with the surrounding tissue.

Discussion {#s4}
==========

Gastric cancer results in a poor prognosis because of frequent metastatic processes, such as LN metastasis and peritoneal metastasis [@pone.0110736-Hippo1]. CSCs have been proposed as having an important role in the malignant potential of cancer cells, including distant metastasis and chemoresistance [@pone.0110736-Glinsky1]. We have since discovered that SP cells obtained from gastric cancer subjects possess these CSC properties [@pone.0110736-Nishii1]. We confirmed that SP cells utilized in this study express candidate gastric cancer stem cell markers including CD44[@pone.0110736-Takaishi2], CD133 [@pone.0110736-Wen1], and NANOG [@pone.0110736-Liu1] (**[Figure S2](#pone.0110736.s002){ref-type="supplementary-material"}**). The spheroid colony formation activity of these SP cells was higher than that of the parent cells [@pone.0110736-Hasegawa1]. Also, these CSC-like SP cells display chemoresistance to anticancer drugs [@pone.0110736-Yashiro1]. These findings have confirmed that OCUM-12/SP cells and OCUM-2MD3/SP cells may represent cancer stem cell-like properties. Since specific markers for gastric CSCs have not been published as of yet, elucidation of the specific signaling pathways and mechanisms underlying the actions of CSCs might improve the prognosis of gastric cancer. In this study, eight candidate CSCs markers were identified by proteomic techniques using LC-MS/MS coupled with iTRAQ technology. Three proteins, RBBP6, GLG1 and VPS13A, were detected only in SP cell lines but not in their respective parent cell lines. In addition, the five proteins, HSPA9, ALDOA, DCTPP1, HSPA4, and KRT18, were over-expressed in both SP cell lines relative to their respective parent cell lines. RT-PCR analysis also indicated that the expression level of *RBBP6, HSPA4, DCTPP1, HSPA9, VPS13A, ALDOA, GLG1*, and *CK18* was high in OCUM-12/SP and OCUM-2MD3/SP, in compared with the control of parent OCUM-12 and OCUM-2MD3. These proteins were suspected to be novel biomarkers for gastric CSCs. This hypothesis was tested by immunohistochemical analysis of 300 gastric cancer cases.

RBBP6 is a nuclear protein, which is a known to be associated and potentially related to p53, and retinoblastoma binding Q protein 1 (RBQ-1) [@pone.0110736-Chibi1]. RBBP6 interacts with the tumor suppressor proteins p53 and Rb, and plays a role in the induction of apoptosis as well as regulating the cell cycle [@pone.0110736-Scott1], [@pone.0110736-Pugh1]. RBBP6 binds to wild-type p53 proteins but not to p53 mutants [@pone.0110736-Simons1]. It has also been shown to promote the binding of MDM2 [@pone.0110736-Midgley1], an E3 ubiquitin ligase that targets the p53[@pone.0110736-Yoshitake1], and to interfere with its ability to transactivate the target genes [@pone.0110736-Li2]. Up-regulation of RBBP6 has been strongly correlated with tumor progression in esophageal cancer and cervical cancer [@pone.0110736-Yoshitake1]. In this study, RBBP6 expression was associated with 'T' category cancer with regards to invasion depth, distant metastasis, lymph node metastasis, and clinical stage. Moreover, RBBP6 expression was significantly associated with poor survival in patients at all stages, particularly at stage III, resulting in the conclusion that RBBP6 was an independent factor for survival. We performed the *RBBP6* siRNA knockdown of *RBBP6* gene using OCUM-12/SP cells and OCUM-2MD3/SP cells in this study. *RBBP6* siRNA knockdown significantly decreased the invasion and migration activity of both SP cells, while the sphere forming activity was not different between the negative-siRNA and *RBBP6* siRNA in SP cells (data not shown). IHC analysis also indicated that RBBP6 expression was associated with invasion depth, LN metastasis, distant metastasis, and a poor prognosis in gastric cancer patients. RBBP6 might be a novel biomarker of gastric CSCs for clinical diagnosis. These findings suggested that RBBP6 might be closely associated with malignant potential of cancer stem cells, rather than stem cell phenotype.

GLG1 is known as a cysteine-rich fibroblast growth factor receptor (FGFR) [@pone.0110736-Kibriya1]. GLG1 was concluded to be associated with the tumorigenesis of some carcinomas [@pone.0110736-CrnogoracJurcevic1] and malignancy of brain tumors [@pone.0110736-Yamaguchi1]. FGFR signaling possesses broad mitogenic and cell survival mechanisms, and is involved in a variety of biological processes, including embryonic development, cell growth, and tumor invasion [@pone.0110736-Kibriya1]. As observed in this study, GLG1 was concluded to be significantly associated with T category cancer with regards to invasion depth. It should be noted that GLG1 may be associated with invasion potential of CSCs via FGFR signaling.

Vacuolar protein sorting (VPS) plays a crucial role in the trafficking of molecules between cellular organelles, such as through the trans-Golgi network. The mutation in this gene causes the autosomal disorder characterized by progressive neurodegeneration. A past study found that frameshift mutations of VPS genes, along with loss of expression of VPS13A proteins, are common in gastric cancers with high microsatellite instability and suggests that these alterations may contribute to the development of cancer [@pone.0110736-An1]. VPS is involved in cancer-related cellular mechanisms, such as proliferation [@pone.0110736-Thompson1], [@pone.0110736-Vaccari1]. As observed in this study, VPS13A was expressed in SP cells and was concluded to be associated with a T category cancer and lymph node metastasis of gastric cancer. It should be noted that VPS13A may be associated with the invasion potential of CSCs.

DCTPP1 is expressed in the nucleus of various cancer cells. Zhang et al. suggested that the accumulation of DCTPP1 in the nucleus of tumor cells might be sufficient for maintaining proper DNA replication needed in order to fulfill the requirement for survival and proliferation of the cells [@pone.0110736-Zhang1]. In conclusion, DCTPP1 was determined to be significantly associated with metastatic activity. It should be noted that DCTPP1 may be associated with the DNA replication of CSCs.

HSPA9 and HSPA4 were concluded to be associated with the invasion and metastatic activity of gastric cancer. These two proteins are members of the heat shock protein (HSP)-70 family of chaperones, and HSPA9 is the major protein in the mitochondria. Some studies have suggested that HSPA9 and HSPA4 are relevant to cellular apoptosis and promoting proliferation[@pone.0110736-Yenari1], ; HSPA9 is over-expressed in colon and hepatocellular carcinomas [@pone.0110736-Peng1], [@pone.0110736-Gestl1], while HSPA4 is over-expressed in breast, colon, ovarian, and pancreatic cancers [@pone.0110736-Zhong1]. The HSPA4/HSPA14 axis induces the migration, invasion, and transformation of cancer cells [@pone.0110736-Wu1]. HSP27 regulates EMT processes and NF-κB activity to contribute to the maintenance of breast CSCs [@pone.0110736-Wei1]. Inhibition of the HSP70 protein reduced adhesion and induced apoptosis of both acquired and *de novo* drug resistant cancer cells [@pone.0110736-Nimmanapalli1]. The HSPA9 protein is one of the markers of a colon cancer stem cell population [@pone.0110736-Giampieri1]. In conclusion, these findings suggest that HSPA9 and HSPA4 are associated with CSCs properties via chaperones for EMT-associated molecules.

ALDOA, aldolase isozymes, is a key glycolytic enzyme that catalyzes the reversible conversion of fructose-1,6-bisphosphate into glyceraldehyde 3-phosphate and dihydroxyacetone phosphate [@pone.0110736-Kajita1]. Glycolysis is one of the key factors for CSC properties. ALDOA has been expressed in a variety of cancers, such as lung cancer, renal cell and hepatocellular carcinoma [@pone.0110736-Shimizu1], [@pone.0110736-Du1]. As observed in this study, ALDOA was concluded to be significantly associated with the malignant potential of gastric cancer with regards to invasion depth, LN metastasis, and clinical stage. In addition, these findings suggest that ALDOA may be associated with the glycolysis of CSCs.

KRT18 is a type I intermediate filament and its filament partner is keratin 8 (KRT8). KRT18 is involved in intracellular signaling pathways that regulate cell growth [@pone.0110736-Fortier1]. Fortier et al. currently reported that KRT18/KRT8 is associated with the epithelial-mesenchymal transition (EMT) of cancer cells [@pone.0110736-Fortier1]. EMT is ultimately thought to promote tumor progression through the generation of CSC properties [@pone.0110736-Polyak1], [@pone.0110736-Devarajan1]. These findings suggested that KRT18 may be associated with the EMT of CSCs.

We previously reported on the proteomic differential display analysis of normal gastric mucosal tissues and human gastric carcinoma cell lines, including OCUM-12 and OCUM-2MD3 [@pone.0110736-Kuramitsu1]. Nineteen protein spots were observed to be up-regulated in SGC cell lines when compared to normal gastric mucosa tissues by using 2-DE and LC-MS/MS. Among the identified increased spots, two proteins, including UDP-glucose 6-dehydrogenase and the electron transfer flavoprotein subunit alpha, were also up-regulated in OCUM-12/SP cells, as opposed to OCUM-12 cells. Three proteins, including nucleophosmin, peroxiredoxin-1, and elongation factor were up-regulated in OCUM-2MD3/SP cells, as opposed to OCUM-2M cells. Conversely, three proteins, 14-3-3 protein sigma, glucosidase 2 subunit beta, and protein DJ-1, were down-regulated in OCUM-12/SP cells as opposed to OCUM-12 cells in this study. Overall, the eight proteins, UDP-glucose 6-dehydrogenase, electron transfer flavoprotein, nucleophosmin, peroxiredoxin-1, elongation factor, 14-3-3 protein sigma, glucosidase 2 subunit beta, and protein DJ-1 may be associated with CSCs as well. To the best of our knowledge, this is the first proteomic analysis that provides evidence that HSPA9, ALDOA, DCTPP1, HSPA4, KRT18, RBBP6, GLG1, and VPS13A may be candidate CSC markers for gastric cancer. In particular, RBBP6 may be a promising predictive marker for the prognosis of patients with gastric cancer.
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###### 

**Representative picture of side population fraction.** Cancer cells, which disappear in the presence of verapamil (lower panel), are outlined and defined as the SP cells. OCUM-12/SP and OCUM-2MD3/SP cells were sorted as SP cells from each of the parent OCUM-12 and OCUM-2MD3 cells, respectively. The percentages of SP cells were higher in the OCUM-12/SP and OCUM-2MD3/SP cells than in their parent OCUM-12 and OCUM-2MD3 cells.

(TIF)

###### 

Click here for additional data file.

###### 

**Stem cell markers expression.** The expression level of CSC markers, ***CD44*** **, CD133 and** ***NANOG*** was significantly higher in OCUM-12/SP (1.6-, 3.6- and 33.2-fold) and OCUM-2MD3/SP cells (2.1-, 5.9- and 3.6-fold) than that in parent OCUM-12 and OCUM-2MD3 cells.

(TIF)

###### 

Click here for additional data file.

###### 

**Expression of RBBP6 and ALDOA.** The expression level of RBBP6 and ALDOA was high in CUM-12/SP and OCUM-2MD3/SP cells, in comparison with that OCUM-12 and OCUM-2MD3 cells.

(TIF)

###### 

Click here for additional data file.

###### 

(DOCX)

###### 

Click here for additional data file.

###### 

**Proteins increased in both OCUM-12/SP and OCUM-2MD3/SP cells.**

(DOCX)

###### 

Click here for additional data file.

###### 

(DOCX)

###### 

Click here for additional data file.
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